Michael J Overman, M.D.

Peer-Reviewed Articles

1. Pattalachinti, V, Haque, E, Yousef, M, Yousef, A, Chowdhury, S, Overman, MJ, Parseghian, C, Morris, VK, Kee, BK, Huey, RW, Raghav, KS, Court, CM, Shen, JY. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 39910160.
2. Raghav, KS, Guthrie, KA, Tan, BR, Denlinger, CS, Fakih, MG, Overman, MJ, Dasari, NV, Corum, LR, Hicks, LG, Patel, MS, Esparaz, BT, Kazmi, SM, Alluri, N, Colby, S, Gholami, S, Gold, PJ, Chiorean, EG, Kopetz, S, Hochster, HS, Philip, PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613). Journal of Clinical Oncology 43(11):1348-1357, 2025. e-Pub 2025. PMID: 39761503.
3. Holowatyj, AN, Overman, MJ, Votanopoulos, K, Lowy, AM, Wagner, P, Washington, MK, Eng, C, Foo, WC, Goldberg, RM, Hosseini, M, Idrees, K, Johnson, DB, Shergill, A, Ward, EP, Zachos, N, Shelton, D. Defining a ‘cells to society’ research framework for appendiceal tumours. Nature Reviews Cancer 25(4):293-315, 2025. e-Pub 2025. PMID: 39979656.
4. Schoenfeld, JD, Azad, N, Gross, JM, Chen, L, Overman, MJ, Kao, K, Jackson, L, Brunnquell, D, Bu, X, Coppola, C, Guan, P, Lee, J, Sims, DJ, Fuchs, R, Weirather, JL, Pfaff, KL, Gunasti, L, Ranasinghe, S, Hamilton, SR, Wang, V, O'Dwyer, PJ, Wu, C, Rodig, SJ, Patton, DR, Harris, LN. Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab. Clinical Cancer Research 31(4):667-677, 2025. e-Pub 2025. PMID: 39670863.
5. Nasca, V, Zhao, J, Ros, J, Lonardi, S, Zwart, K, Cohen, R, Fakih, MG, Jayachandran, P, Roodhart, JM, Derksen, JW, Intini, R, Bergamo, F, Mazzoli, G, Ghelardi, F, Ligero, M, Jonnagaddala, J, Hawkins, N, Ward, R, Wankhede, D, Brenner, H, Hoffmeister, M, Vitellaro, M, Salvatore, L, Gallois, C, Laurent-Puig, P, Cremolini, C, Overman, MJ, Taieb, J, Tougeron, D, Andre, T, Kather, JN, Sundar, R, Carmona, J, Elez, E, Koopman, M, Pietrantonio, F. Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 39929672.
6. White, MG, Zeineddine, MA, Fallon, EA, Zeineddine, F, Dansby, J, Chowdhury, S, Hornstein, N, Yousef, A, Yousef, M, Bhutiani, N, Gu, Y, Kee, BK, Dasari, NV, Overman, MJ, Raghav, KS, Kopetz, S, Uppal, A, Taggart, MW, Newhook, TE, Fournier, KF, Helmink, BA, Drusbosky, L, Shen, JY. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clinical Cancer Research 31(3):551-560, 2025. e-Pub 2025. PMID: 39679931.
7. Taieb, J, Ambrosini, M, Alouani, E, Lonardi, S, Sinicrope, FA, Decraecker, M, Boilève, A, Hafliger, E, Mazard, T, Pernot, S, Parent, P, Ros, J, Overman, MJ, Jayachandran, P, Nasca, V, Salvatore, L, Guimbaud, R, Cremolini, C, Tougeron, D, Pietrantonio, F. Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. Journal for immunotherapy of cancer 13(1), 2025. e-Pub 2025. PMID: 39755579.
8. Yennu, S, Valero, V, Smalgo, BG, Overman, MJ, Dasari, A, Wolff, RA, Raghav, KS, Barcenas, CH, Busaidy, NL, Fellman, B, Basen-Engquist, KM, Hess, KR, Tripathy, D, Bruera, E. Physical Activity and Dexamethasone for Cancer-Related Fatigue. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39773433.
9. Yousef, M, Hurd, MW, Yousef, A, Ludmir, EB, Balachandran Pillai, A, Peterson, J, Koay, EJ, Albarouki, S, Tzeng, CW, Snyder, RA, Katz, MH, Wang, H, Overman, MJ, Maitra, A, Pant, S, Smaglo, BG, Wolff, RA, Yao, JC, Shen, JY, Zhao, D. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39014543.
10. Ecker, BL, Seier, K, Eckhoff, AM, Tortorello, GN, Allen, PJ, Balachandran, VP, Blackburn, N, D'Angelica, M, Dematteo, RP, Blazer, DG, Drebin, JA, Fisher, WE, Fortuna, D, Gill, AJ, Gingras, MC, Kingham, TP, Lee, MK, Lidsky, ME, Nussbaum, DP, Overman, MJ, Samra, JS, Shen, R, Sigel, C, Soares, KC, Vollmer, CM, Wei, AC, Zani, S, Roses, RE, Gonen, M, Jarnagin, W. Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication. JAMA Surgery 159(12), 2024. e-Pub 2024. PMID: 39259526.
11. Yousef, A, Yousef, M, Chowdhury, S, Abdilleh, K, Knafl, M, Edelkamp, P, Alfaro-Munoz, KD, Chacko, R, Peterson, J, Smaglo, BG, Wolff, RA, Pant, S, Lee, MS, Willis, JA, Overman, MJ, Doss, S, Matrisian, L, Hurd, MW, Snyder, RA, Katz, MH, Wang, H, Maitra, A, Shen, JP, Zhao, D. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38310130.
12. Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
13. Holla, V, Kahle, M, Kim, SH, Ronaghy, A, Yang, RK, Patel, KP, Routbort, MJ, Overman, MJ, Ileana Dumbrava, EE, Mills Shaw, KR, Karp, DD, Meric-Bernstam, F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39576951.
14. Margalit, O, Stemmer, A, Chapin, WJ, Shacham-Shmueli, E, Kopetz, S, Andre, T, Overman, MJ, Pietrantonio, F, Boursi, B. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. European Journal of Cancer 212, 2024. e-Pub 2024. PMID: 39316932.
15. Coveler, A, Reilley, MJ, Zalupski, M, Macarulla, T, Fountzilas, C, Ponz, M, Nagrial, AM, Uboha, NA, Frentzas, S, Overman, MJ, Noonan, AM, Messersmith, WA, Pavlakis, N, Mettu, NB, Bisha, I, Wang, Y, Smith, P, Murtomaki, E, Bielska, AA, Bragulat, V, Cooper, Z, Kumar, R, Spigel, D. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research 30(20):4609-4617, 2024. e-Pub 2024. PMID: 39106081.
16. Beck, EJ, Sherry, AD, Florez, MA, Kouzy, R, Abi Jaoude, J, Lin, TA, Miller, AM, Passy, AH, Kupferman, GS, Patel, RR, Chino, F, Serpas Higbie, V, Parseghian, C, Overman, MJ, Minsky, B, Thomas, CR, Tang, C, Msaouel, P, Ludmir, EB. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Cancer Research Communications 4(8):2183-2188, 2024. e-Pub 2024. PMID: 39099199.
17. Ambrosini, M, Rousseau, B, Manca, P, Artz, O, Marabelle, A, Andre, T, Maddalena, G, Mazzoli, G, Intini, R, Cohen, R, Cercek, A, Segal, NH, Saltz, L, Varghese, AM, Yaeger, R, Nusrat, M, Goldberg, Z, Ku, GY, El Dika, I, Margalit, O, Grinshpun, A, Murtaza Kasi, P, Schilsky, RL, Lutfi, A, Shacham-Shmueli, E, Khan Afghan, M, Weiss, L, Westphalen, CB, Conca, V, Decker, B, Randon, G, Elez, E, Fakih, MG, Schrock, AB, Cremolini, C, Jayachandran, P, Overman, MJ, Lonardi, S, Pietrantonio, F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Annals of Oncology 35(7):643-655, 2024. e-Pub 2024. PMID: 38777726.
18. Chang, E, Wong, FC, Chasen, B, Erwin, WD, Das, P, Holliday, EB, Koong, A, Ludmir, EB, Minsky, B, Noticewala, SS, Smith, GL, Taniguchi, C, Rodriguez, MJ, Beddar, S, Martin, RM, Niedzielski, JS, Sawakuchi, GO, Schueler, E, Perles, LA, Xiao, L, Szklaruk, J, Park, PC, Dasari, NV, Kaseb, A, Kee, BK, Lee, SS, Overman, MJ, Willis, JA, Wolff, RA, Tzeng, CD, Vauthey, JN, Koay, EJ. Phase i trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectrum 8(3), 2024. e-Pub 2024. PMID: 38730548.
19. Benson, AB, Venook, AP, Adam, M, Chang, GJ, Chen, YJ, Ciombor, KK, Cohen, S, Cooper, HS, Deming, DA, Garrido-Laguna, I, Grem, JL, Haste, P, Hecht, JR, Hoffe, S, Hunt, S, Hussan, H, Johung, KL, Joseph, N, Kirilcuk, N, Krishnamurthi, SS, Malla, M, Maratt, JK, Messersmith, WA, Meyerhardt, JA, Miller, ED, Mulcahy, MF, Nurkin, S, Overman, MJ, Parikh, AR, Patel, H, Pedersen, KS, Saltz, L, Schneider, CJ, Shibata, D, Shogan, BD, Skibber, JM, Sofocleous, CT, Tavakkoli, A, Willet, CG, Wu, CS, Gurski, LA, Snedeker, J, Jones, F. Colon Cancer, Version 3.2024. JNCCN Journal of the National Comprehensive Cancer Network 22(2d), 2024. e-Pub 2024. PMID: 38862008.
20. Overman, MJ, Gelsomino, F, Aglietta, M, Wong, M, Limon Miron, ML, Leonard, GD, García-Alfonso, P, Hill, AG, Cubillo Gracian, A, Van Cutsem, E, El-Rayes, B, McCraith, SM, He, B, Lei, M, Lonardi, S. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Journal for immunotherapy of cancer 12(5), 2024. e-Pub 2024. PMID: 38821718.
21. Hornstein, N, Zeineddine, MA, Gunes, BB, Pellatt, AJ, Knafl, M, Zhu, H, Willett, A, Yousef, A, Liu, S, Sun, R, Futreal, A, Woodman, SE, Taggart, MW, Overman, MJ, Halperin, DM, Raghav, KS, Shen, JY. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Research Communications 4(5):1363-1368, 2024. e-Pub 2024. PMID: 38709066.
22. Cohen, R, Raeisi, M, Chibaudel, B, Yoshino, T, Shi, Q, Zalcberg, J, Adams, RA, Cremolini, C, Grothey, A, Mayer, RJ, Van Cutsem, E, Tabernero, J, Bando, H, Misumi, T, Overman, MJ, Andre, T, De Gramont, A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms. European Journal of Cancer 199, 2024. e-Pub 2024. PMID: 38241818.
23. Yousef, A, Yousef, M, Zeineddine, MA, More, A, Fanaeian, M, Chowdhury, S, Knafl, M, Edelkamp, P, Ito, I, Gu, Y, Pattalachinti, V, Naini, ZA, Zeineddine, F, Peterson, J, Alfaro, KD, Foo, WC, Jin, J, Bhutiani, N, Higbie, V, Scally, CP, Kee, BK, Kopetz, S, Goldstein, D, Strach, M, Williamson, A, Aziz, O, Barriuso, J, Uppal, A, White, MG, Helmink, BA, Fournier, KF, Raghav, KS, Taggart, MW, Overman, MJ, Shen, JY. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Network Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
24. Amaria, RN, Knisely, A, Vining, D, Kopetz, S, Overman, MJ, Javle, M, Antonoff, MB, Tzeng, CD, Wolff, RA, Pant, S, Lito, K, Rangel, KM, Fellman, B, Yuan, Y, Lu, KH, Sakellariou-Thompson, D, Haymaker, CL, Forget, MA, Hwu, P, Bernatchez, C, Jazaeri, AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
25. Johnson, B, Morris, VK, Wang, X, Dasari, NV, Raghav, KS, Shen, JY, Lee, MS, Huey, RW, Parseghian, C, Willis, JA, Wolff, RA, Drusbosky, L, Overman, MJ, Kopetz, S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers 16(4), 2024. e-Pub 2024. PMID: 38398128.
26. Stemmer, A, Margalit, O, Serpas Higbie, V, Strauss, G, Thomas, J, Shah, P, Tau, N, Levanon, K, Shacham-Shmueli, E, Kopetz, S, Overman, MJ, Boursi, B. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer – Outcome and novel predictive markers. European Journal of Cancer 198, 2024. e-Pub 2024. PMID: 38157568.
27. Bhutiani N, Grotz TE, Concors SJ, White MG, Helmink BA, Raghav KP, Taggart MW, Beaty KA, Royal RE, Overman MJ, Matamoros A, Scally CP, Rafeeq S, Mansfield PF, Fournier KF. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol 31(1):614-621, 2024. e-Pub 2023. PMID: 37872456.
28. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist 28(12):e1303-e1305, 2023. e-Pub 2023. PMID: 37738316.
29. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
30. Janczewski LM, Browner AE, Cotler JH, Nelson H, Kakar S, Carr NJ, Hanna NN, Holowatyj AN, Goldberg RM, Washington MK, Asare EA, Overman MJ, Disease Site AJCOCEPOCFTLGA. Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer. CA Cancer J Clin 73(6):590-596, 2023. e-Pub 2023. PMID: 37358310.
31. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer 194:113356, 2023. e-Pub 2023. PMID: 37827065.
32. Yousef A, Yousef M, Zeineddine M, More A, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine F, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally C, Kee B, Kopetz S, Goldstein D, Uppal A, White MG, Helmink B, Fournier K, Raghav K, Taggart M, Overman MJ, Shen JP. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv, 2023. e-Pub 2023. PMID: 37745596.
33. Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, Corti F, Jayachandran P, Svrcek M, Dardenne A, Cervantes B, Duval A, Cohen R, Pietrantonio F, André T. BRAFV600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist 28(9):771-779, 2023. e-Pub 2023. PMID: 37023721.
34. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
35. Zhang Y, Wang H, Overman M, Katz MH, Wang H. Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma. Hum Pathol 139:117-125, 2023. e-Pub 2023. PMID: 37516386.
36. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq, 2023. e-Pub 2023. PMID: 37609177.
37. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and Value of Genomic-Profiling in Cancer of Unknown Primary: Real-World Evidence from Prospective Profiling Study. J Natl Cancer Inst 115(8):994-997, 2023. e-Pub 2023. PMID: 37202363.
38. Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother 72(7):2443-2458, 2023. e-Pub 2023. PMID: 37016126.
39. Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier K. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open 6(6):e2316161, 2023. e-Pub 2023. PMID: 37261831.
40. Offodile AC, Delgado D, Lin YL, Geyen D, Miller CJ, Jain S, Finder JP, Shete S, Fossella FV, Overman MJ, Peterson SK. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract 19(6):e811-e821, 2023. e-Pub 2023. PMID: 36821818.
41. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21(6):653-677, 2023. e-Pub 2023. PMID: 37308125.
42. Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. Publisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep 13(1):8318, 2023. e-Pub 2023. PMID: 37221249.
43. Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, Thomas CR, Ludmir EB. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open 6(5):e2313819, 2023. e-Pub 2023. PMID: 37195664.
44. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg 10(5):813-820, 2023. e-Pub 2022. PMID: 35797554.
45. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
46. Vikas P, Messersmith H, Compton C, Sholl L, Broaddus RR, Davis A, Estevez-Diz M, Garje R, Konstantinopoulos PA, Leiser A, Mills AM, Norquist B, Overman MJ, Sohal D, Turkington RC, Johnson T. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol 41(10):1943-1948, 2023. e-Pub 2023. PMID: 36603179.
47. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh) 7(4):e2101319, 2023. e-Pub 2023. PMID: 35343107.
48. Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, Smaglo BG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MHG, Tzeng CD. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg 277(3):484-490, 2023. e-Pub 2023. PMID: 36649067.
49. Erstad DJ, Robinson KA, Beaty K, Rafeeq S, Chiang YJ, Raghav K, Shen JP, Overman MJ, Foo WC, Taggart MW, Mansfield PF, Royal RE, Fournier KF, Scally CP. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg 408(1):110, 2023. e-Pub 2023. PMID: 36853519.
50. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
51. Anandappa G, Overman MJ. Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. Cell Rep Med 4(1):100908, 2023. e-Pub 2023. PMID: 36652917.
52. Anandappa G, Overman M. Cell Reports Medicine. Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer, 2023. e-Pub 2023.
53. Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer 11(1), 2023. e-Pub 2023. PMID: 36593068.
54. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
55. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys 114(3):444-453, 2022. e-Pub 2022. PMID: 35863672.
56. Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep 12(1):19023, 2022. e-Pub 2022. PMID: 36348045.
57. Bartley AN, Mills AM, Konnick E, Overman M, Ventura CB, Souter L, Colasacco C, Stadler ZK, Kerr S, Howitt BE, Hampel H, Adams SF, Johnson W, Magi-Galluzzi C, Sepulveda AR, Broaddus RR. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med 146(10):1194-1210, 2022. e-Pub 2022. PMID: 35920830.
58. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
59. André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol 33(10):1052-1060, 2022. e-Pub 2022. PMID: 35764271.
60. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(10):1139-1167, 2022. e-Pub 2022. PMID: 36240850.
61. Mazzoli G, Cohen R, Lonardi S, Corti F, Elez E, Fakih M, Jayachandran P, Colle R, Shah AT, Salati M, Fenocchio E, Salvatore L, Ambrosini M, Ros J, Intini R, Cremolini C, Overman MJ, André T, Pietrantonio F. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer 172:171-181, 2022. e-Pub 2022. PMID: 35777274.
62. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
63. Yu K, Mathew A, Abraham F, Amin R, Kono M, Overman M, Zhao D, Khan A, Khan MA, Thomas AS, Wang Y. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann Gastroenterol 35(5):514-521, 2022. e-Pub 2022. PMID: 36061157.
64. Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw 20(8):887-897.e3, 2022. e-Pub 2022. PMID: 35948035.
65. Bartley AN, MD, Mills AM, MD, Konnick E, MD, MS, Overman M, MD, Ventura CB, MPH, MT(ASCP), Souter L, PhD, Colasacco C, MLIS, SCT(ASCP), Stadler ZK, MD, Kerr S, MD, Howitt BE, MD, Hampel H, MS, LGC, Adams SF, MD, Johnson W, BS, Magi-Galluzzi C, MD, PhD, Sepulveda AR, MD, PhD, Broaddus RR, MD, PhD. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy. College of American Pathologist, 2022. e-Pub 2022.
66. D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci Transl Med 14(657):eabo7604, 2022. e-Pub 2022. PMID: 35947675.
67. 1 BJ, Haymaker 2 CL, Parra 2 ER, Soto 2 LMS, 3 XW, Thomas 4 JV, 4 AD, Morris 4 VK, 4 KR, 4 5 EV, Kee 4 BK, 6 CE, Parseghian 4 CM, Wolff 4 RA, 2 YL, 2 DL, 2 CL, 2 AV, 2 WL, Wistuba 2 II, 2 AF, 4 SK, Overman 4 MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). National Library of medicine 10(8), 2022. e-Pub 2022. PMID: 36007963.
68. Willis JA, Overman MJ. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response. Cancer Discov 12(7):1612-1614, 2022. e-Pub 2022. PMID: 35791694.
69. Willis JA, Overman MJ. Inducing Hypermutability to Promote Anti–PD-1 Therapy Response. Cancer discovery 12(7):1612-1614, 2022. e-Pub 2022.
70. Overman MJ, Lenz H, Andre T, Aglietta M, Wong MK, Luppi G, Cutsem EV, McDermott RS, Hendlisz A, Cardin DB, Morse M, Neyns B, Hill AG, M Luisa Limon M, Garcia-Alfonso P, Krishnamurthy A, Chen F, Abdullaev S, Soleymani S, Lonardi S. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. Journal of Clinical Oncology(40):3510-3510. e-Pub 2022.
71. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
72. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
73. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg 109(6):489-492, 2022. e-Pub 2022. PMID: 35576377.
74. Nishioka Y, Chun YS, Overman MJ, Cao HST, Tzeng CD, Mason MC, Kopetz SW, Bauer TW, Vauthey JN, Newhook TE, MD Anderson Cancer Center INTERCEPT Program MD. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg 234(4):474-483, 2022. e-Pub 2022. PMID: 35290266.
75. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
76. Offodile AC, DiBrito SR, Finder JP, Shete S, Jain S, Delgado DA, Miller CJ, Davidson E, Overman MJ, Peterson SK. Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. BMJ Open 12(4):e057693, 2022. e-Pub 2022. PMID: 35383081.
77. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2021. PMID: 34794903.
78. Thibodeau S N, Bren G, colon[J] Science SDMIICOTP, 1993, J Overman 28[M, McDermott R, Leach JL, an open-label EANIPWMDMRDCC(1RO, multicenter, Lancet Oncology P2S, 2017, Aurelien Marabelle 1[, Le DT, Asciert PA, Clin Oncol EAEOPIPWNHMIRCRFTPISJ, 2020, [4] Chen 31, W, al E, in China CS, J Clin 2CC, 2016. Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG. Intellasia. net, 2022. e-Pub 2022.
79. Pandya K, Overman MJ, Gulhati P. Molecular Landscape of Small Bowel Adenocarcinoma. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267592.
80. Thibodeau S N, Bean, Overman MJ, Marabelle A, Chen, W. Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG Read more at: https://www.lelezard.com/en/news-20305152.html. Le Lezard 38(1):1-10, 2022. e-Pub 2022.
81. Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, Koong AC, Holliday EB, Taniguchi CM, Katz MHG, Tamm EP, Wolff RA, Overman MJ, Patel S, Kim MP, Tzeng CD, Ikoma N, Bhutani MS, Koay EJ. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol 33:66-69, 2022. e-Pub 2022. PMID: 35097226.
82. Pandya K, Pat Gulhati MJO. Molecular Landscape of Small Bowel Adenocarinoma. Cancer MDPI, 2022. e-Pub 2022.
83. Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110358.
84. Moati E, Overman MJ, Zaanan A. Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267446.
85. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
86. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol 40(2):JCO2101015, 2022. e-Pub 2022. PMID: 34637336.
87. Randon G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, Fucà G, Brich S, Cattaneo L, Fassan M, Pietrantonio F, Lonardi S. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur J Cancer 161:90-98, 2022. e-Pub 2022. PMID: 34933155.
88. Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol 12:994333, 2022. e-Pub 2022. PMID: 36212401.
89. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
90. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol 12(5):2268-2274, 2021. e-Pub 2021. PMID: 34790391.
91. Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol 5(1):94, 2021. e-Pub 2021. PMID: 34707215.
92. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, Vanderwalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res 27(16):4587-4598, 2021. e-Pub 2021. PMID: 34117033.
93. Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open 4(8):e2119934, 2021. e-Pub 2021. PMID: 34357397.
94. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage 62(2):223-232.e1, 2021. e-Pub 2021. PMID: 33388382.
95. Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med 10(15):5041-5050, 2021. e-Pub 2021. PMID: 34250759.
96. Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34429334.
97. Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, Bekaii-Saab T, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma. Clin Cancer Res 27(13):3641-3648, 2021. e-Pub 2021. PMID: 33883178.
98. Mason MC, Tzeng CD, Tran Cao HS, Aloia TA, Newhook TE, Overman MJ, Kopetz SE, Vauthey JN, Chun YS. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg 233(1):82-89.e1, 2021. e-Pub 2021. PMID: 33667566.
99. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis 108:419-421, 2021. e-Pub 2021. PMID: 34087489.
100. Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clin Cancer Res 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
101. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
102. Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, Serpas V, Thomas J, Sun R, Wolff RA, Raghav K, Overman MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3):100132, 2021. e-Pub 2021. PMID: 33940348.
103. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
104. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg 273(4):806-813, 2021. e-Pub 2021. PMID: 31274655.
105. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
106. Kadakia KT, Asaad M, Adlakha E, Overman MJ, Checka CM, Offodile AC. Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions. JCO Clin Cancer Inform 5:421-425, 2021. e-Pub 2021. PMID: 33830789.
107. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res 27(6):1663-1670, 2021. e-Pub 2021. PMID: 33414133.
108. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(3):329-359, 2021. e-Pub 2021. PMID: 33724754.
109. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2021. PMID: 32294214.
110. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2021. PMID: 32960478.
111. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021. PMID: 33109741.
112. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250391.
113. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021. PMID: 34367949.
114. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman MJ, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
115. Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer 19(4):e189-e199, 2020. e-Pub 2020. PMID: 32680816.
116. Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Hecht JR, Tournigand C, Tebbut N, Chibaudel B, Gramont A, Shi Q, Overman MJ. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. J Natl Cancer Inst 112(11):1127-1136, 2020. e-Pub 2020. PMID: 32191317.
117. Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist 25(11):e1807-e1811, 2020. e-Pub 2020. PMID: 32893931.
118. Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6), 2020. e-Pub 2020. PMID: 33188051.
119. Kamarinos NV, Dawson LA, Saltz LB, Crane CH, Overman, MJ, Vauthey JN, Odisio BC, Denys A, de Baère T, Pereira PL, Sze DY, Vogl TJ, Meijerink MR, Helmberger T, Kim HS, Solomon SB, Sofocleous CT. Trials of locoregional therapies inspired by SABR-COMET. Lancet 396(10256):956-957, 2020. e-Pub 2020. PMID: 33010838.
120. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg 155(9):832-839, 2020. e-Pub 2020. PMID: 32667641.
121. Hill A, Elakkad A, Kuban J, Sabir S, Odisio B, Huang SY, Mahvash A, Miller E, Kroll MH, Overman, MJ, Tam AL, Gupta S, Sheth RA. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol (NY) 45(9):2886-2894, 2020. e-Pub 2020. PMID: 32314004.
122. Unger JM, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectr 4(4):pkaa034, 2020. e-Pub 2020. PMID: 32704619.
123. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
124. Cheng LC, Chao YJ, Overman, MJ, C- W, Phan NN, Chen YL, Wang TW, Hsu HP, Shan YS, Lai MD. Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Sci Rep 10(1):13255, 2020. e-Pub 2020. PMID: 32764696.
125. Sheth RA, Murthy R, Hong DS, Patel S, Overman, MJ, Diab A, Hwu P, Tam A. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open 3(7):e207911, 2020. e-Pub 2020. PMID: 32725245.
126. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman, MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. e-Pub 2020. PMID: 32733093.
127. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman, MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw 18(7):806-815, 2020. e-Pub 2020. PMID: 32634771.
128. Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman, MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med. e-Pub 2020. PMID: 32663379.
129. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg 271(6):996-1002, 2020. e-Pub 2020. PMID: 31895709.
130. Thomas J, Leal A, Overman, MJ. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer 19(2):73-81, 2020. e-Pub 2020. PMID: 32173280.
131. Yoshino T, Pentheroudakis G, Mishima S, Overman, MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. e-Pub 2020. PMID: 32272210.
132. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman, MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 20(3):501-504, 2020. e-Pub 2020. PMID: 31932214.
133. Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients. Clin Cancer Res 26(6):1385-1394, 2020. e-Pub 2020. PMID: 31871297.
134. Advani SM, Shi Q, Overman, MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
135. Overman, MJ, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32114502.
136. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman, MJ, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. e-Pub 2020. PMID: 32080210.
137. Azad NS, Gray RJ, Overman, MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol 38(3):JCO1900818, 2020. e-Pub 2020. PMID: 31765263.
138. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman MJ, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
139. Overman MJ. Letting go of the physical exam: embracing telehealth solutions to oncology. J Cancer Metastasis Treat 6, 2020. e-Pub 2020. PMID: 34841086.
140. Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst 111(11):1131-1141, 2019. e-Pub 2019. PMID: 31322663.
141. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
142. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
143. Willis JA, Overman MJ, Vilar E. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res 25(17):5185-5187, 2019. e-Pub 2019. PMID: 31263028.
144. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw 17(9):1135-1141, 2019. e-Pub 2019. PMID: 31487680.
145. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17(9):1109-1133, 2019. e-Pub 2019. PMID: 31487687.
146. Johnson B, Loree J, Jacome A, Mendis S, Syed M, Morris VK, Parseghian C, Dasari A, Pant S, Raymond V, Vilar E, Overman MJ, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer, 2019. e-Pub 2019. PMID: 32914034.
147. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
148. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12):2002-2010, 2019. e-Pub 2019. PMID: 30854646.
149. Overman MJ. Immunotherapy in colorectal cancer with mismatch repair deficiency. Clin Adv Hematol Oncol 17(5):265-267, 2019. e-Pub 2019. PMID: 31188802.
150. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. e-Pub 2019. PMID: 31147488.
151. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. e-Pub 2019. PMID: 30905761.
152. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
153. Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer 120(3):340-345, 2019. e-Pub 2019. PMID: 30636774.
154. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
155. Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book 39:207-215, 2019. e-Pub 2019. PMID: 31099678.
156. Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 21(2):5, 2019. e-Pub 2019. PMID: 30701321.
157. Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol 18(1):169, 2018. e-Pub 2018. PMID: 30541475.
158. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer 17(4):e699-e709, 2018. e-Pub 2018. PMID: 30205948.
159. Ko H, Yan M, Gupta R, Kebbel K, Maiti A, Song J, Nates J, Overman MJ. Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. Oncologist. e-Pub 2018. PMID: 30518614.
160. Aldrich JD, Raghav KPS, Varadhachary GR, Wolff RA, Overman MJ. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. e-Pub 2018. PMID: 30598498.
161. Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. e-Pub 2018. PMID: 30383128.
162. Mizrahi JD, Overman MJ. Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury. Oncotarget 9(79):34857-34858, 2018. e-Pub 2018. PMID: 30405879.
163. Adam L, San Lucas FA, Fowler J, Yu Y, Wu W, Liu Y, Wang H, Menter DG, Tetzlaff MT, Ensor JE, Manyam G, Arold ST, Huff CD, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res. e-Pub 2018. PMID: 30352910.
164. O'Keefe CM, Pisanic TR, Zec H, Overman MJ, Herman JG, Wang TH. Facile profiling of molecular heterogeneity by microfluidic digital melt. Sci Adv 4(9):eaat6459, 2018. e-Pub 2018. PMID: 30263958.
165. Sarshekeh AM, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol 14(18):1869-1874, 2018. e-Pub 2018. PMID: 29473436.
166. Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. e-Pub 2018. PMID: 30112590.
167. Overman MJ, Ellis LM, Joffe S. Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. JAMA Oncol 4(8):1041-1042, 2018. e-Pub 2018. PMID: 29799989.
168. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, 2018. e-Pub 2018. PMID: 29668571.
169. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut 67(6):1095-1102, 2018. e-Pub 2018. PMID: 29084828.
170. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol 11(1):71, 2018. e-Pub 2018. PMID: 29843755.
171. Overman MJ, Ernstoff MS, Morse MA. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. Am Soc Clin Oncol Educ Book(38):239-247, 2018. e-Pub 2018. PMID: 30231358.
172. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29718453.
173. Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124(8):1701-1709, 2018. e-Pub 2018. PMID: 29370450.
174. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist 23(3):277-e26, 2018. e-Pub 2018. PMID: 29259073.
175. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36(8):JCO2017769901, 2018. e-Pub 2018. PMID: 29355075.
176. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
177. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
178. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
179. Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS, Group BW. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. Ann Surg Oncol 25(1):179-187, 2018. e-Pub 2018. PMID: 29071660.
180. Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. e-Pub 2018. PMID: 29346573.
181. Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol 8:107, 2018. e-Pub 2018. PMID: 29732316.
182. Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res 23(23):7263-7275, 2017. e-Pub 2017. PMID: 28947567.
183. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
184. Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol 24(13):3954-3963, 2017. e-Pub 2017. PMID: 28980211.
185. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol 24(12):3667-3672, 2017. e-Pub 2017. PMID: 28831698.
186. Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res 23(21):6450-6457, 2017. e-Pub 2017. PMID: 28754815.
187. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg 152(11):1048-1056, 2017. e-Pub 2017. PMID: 28700784.
188. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 3(11):1546-1553, 2017. e-Pub 2017. PMID: 28617917.
189. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol 24(9):2646-2654, 2017. e-Pub 2017. PMID: 28695394.
190. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182-1191, 2017. e-Pub 2017. PMID: 28734759.
191. Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. World J Gastrointest Oncol 9(9):354-362, 2017. e-Pub 2017. PMID: 28979717.
192. Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin Cancer Res 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
193. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
194. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther 16(7):1435-1442, 2017. e-Pub 2017. PMID: 28468778.
195. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 24(7):2031-2039, 2017. e-Pub 2017. PMID: 28124275.
196. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
197. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer 17(1):331, 2017. e-Pub 2017. PMID: 28506255.
198. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 10(1002):1011-1017, 2017. e-Pub 2017. PMID: 27859010.
199. Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High Prevalence of Mutant KRAS in Circulating Exosome-derived DNA from Early Stage Pancreatic Cancer Patients. Ann Oncol 28(4):741-747, 2017. e-Pub 2017. PMID: 28104621.
200. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8). e-Pub 2017. PMID: 28422758.
201. Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 161(2):332-340, 2017. e-Pub 2017. PMID: 27592215.
202. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol 24(1):187-193, 2017. e-Pub 2017. PMID: 27660258.
203. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg 21(1):164-174, 2017. e-Pub 2017. PMID: 27778257.
204. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol 122(1):146-151, 2017. e-Pub 2017. PMID: 28057329.
205. Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. e-Pub 2017. PMID: 28111717.
206. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
207. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
208. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg 20(12):1975-1985, 2016. e-Pub 2016. PMID: 27730398.
209. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
210. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7(41):67495-67506, 2016. e-Pub 2016. PMID: 27542211.
211. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 122(17):2671-9, 2016. e-Pub 2016. PMID: 27243381.
212. Grotz TE, Mansfield PF, Royal RE, Mann GN, Rafeeq S, Beaty KA, Overman MJ, Fournier KF. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Ann Surg Oncol 23(9):2914-9, 2016. e-Pub 2016. PMID: 27027310.
213. Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol 42(9):1378-84, 2016. e-Pub 2016. PMID: 27358198.
214. Overman MJ, Soifer HS, Schueneman AJ, Ensor J, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer 16(668):668, 2016. e-Pub 2016. PMID: 27549176.
215. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
216. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2016. PMID: 26810202.
217. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
218. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer 114(12):1352-61, 2016. e-Pub 2016. PMID: 27272216.
219. Link JT, Overman MJ. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer J 22(3):190-5, 2016. e-Pub 2016. PMID: 27341597.
220. Hoffmann MS, Overman MJ, Nates JL. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. J Community Support Oncol 14(4):178-9, 2016. e-Pub 2016. PMID: 27152518.
221. Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE, Genome Initiative APC, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep 14(4):907-19, 2016. e-Pub 2016. PMID: 26804919.
222. Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, Weiser MR, Overman MJ. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 122(2):213-21, 2016. e-Pub 2016. PMID: 26506400.
223. Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One 11(5):e0154985, 2016. e-Pub 2016. PMID: 27171493.
224. Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med 5(2):239-47, 2016. e-Pub 2016. PMID: 26714799.
225. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
226. Li D, Pise MN, Overman MJ, Liu C, Tang H, Vadhan-Raj S, Abbruzzese JL. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med 4(11):1651-8, 2015. e-Pub 2015. PMID: 26275671.
227. Xia M, Overman MJ, Rashid A, Chatterjee D, Wang H, Katz MH, Fleming JB, Lee JE, Varadhachary GR, Wolff RA, Wang H. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol 46(9):1315-22, 2015. e-Pub 2015. PMID: 26165226.
228. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. e-Pub 2015. PMID: 26405159.
229. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 22(8):2578-84, 2015. e-Pub 2015. PMID: 25582740.
230. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
231. Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw 13(7):865-72, 2015. e-Pub 2015. PMID: 26150580.
232. Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med 139(6):782-90, 2015. e-Pub 2015. PMID: 26030247.
233. Schueneman A, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer 10(172):1038, 2015. e-Pub 2015. PMID: 25989273.
234. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
235. Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M, Glover K, Jones D, Wen S, Fisch MJ. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 23(3):661-70, 2015. e-Pub 2015. PMID: 25160493.
236. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. e-Pub 2015. PMID: 25980577.
237. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
238. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899-906, 2015. e-Pub 2015. PMID: 25516888.
239. Dineen SP, Royal RE, Hughes MS, Sagebiel T, Bhosale P, Overman M, Matamoros A, Mansfield PF, Fournier KF. A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. e-Pub 2015. PMID: 25698402.
240. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112:1088-97, 2015. e-Pub 2015. PMID: 25688736.
241. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. J Cachexia Sarcopenia Muscle 5(4):307-313, 2014. e-Pub 2014. PMID: 24740741.
242. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
243. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
244. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 2014. e-Pub 2014. PMID: 24585723.
245. Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, Katz MH, Fleming JB, Varadhachary GR, Abbruzzese JL, Wang H. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol 45(5):1015-23, 2014. e-Pub 2014. PMID: 24746206.
246. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 22(5):1223-31, 2014. e-Pub 2014. PMID: 24362907.
247. Aburjania N, Truskinovsky AM, Overman MJ, Lou E. Ampulla of Vater Adenocarcinoma in a BRCA2 Germline Mutation Carrier. J Gastrointest Cancer 45(1):87-90, 2014. e-Pub 2014. PMID: 23417715.
248. Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J 20(1):8-14, 2014. e-Pub 2014. PMID: 24445757.
249. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14(1):660, 2014. e-Pub 2014. PMID: 25208577.
250. Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol 44(12):2792-8, 2013. e-Pub 2013. PMID: 24139211.
251. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
252. Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. The Expression of PTEN Is Associated With Improved Prognosis in Patients With Ampullary Adenocarcinoma After Pancreaticoduodenectomy. Arch Pathol Lab Med 137(11):1619-26, 2013. e-Pub 2013. PMID: 24168499.
253. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist. e-Pub 2013. PMID: 24149137.
254. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs 31(5):1375-83, 2013. e-Pub 2013. PMID: 23645398.
255. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 10(9):534-44, 2013. e-Pub 2013. PMID: 23897080.
256. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 2013. e-Pub 2013. PMID: 23704197.
257. Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol 37(8):1192-200, 2013. e-Pub 2013. PMID: 23648460.
258. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg 257(6):1072-8, 2013. e-Pub 2013. PMID: 23001080.
259. Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol 52(5):1044-6, 2013. e-Pub 2013. PMID: 23020527.
260. Shaw C, Bassett RL, Fox PS, Schmeler KM, Overman MJ, Wallace MJ, Gupta S, Tam A. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol 20(2):497-505, 2013. e-Pub 2013. PMID: 22965572.
261. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2013. PMID: 23129736.
262. Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Zhi-Qin J, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8(6):e65144, 2013. e-Pub 2013. PMID: 23776447.
263. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8(10):e77117, 2013. e-Pub 2013. PMID: 24143206.
264. Overman MJ. Rare but real. Am Soc Clin Oncol Educ Book 2013:189-93, 2013. e-Pub 2013. PMID: 23714497.
265. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronousliver metastases. Ann Surg 256(4):642-50, 2012. e-Pub 2012. PMID: 22968062.
266. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
267. Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights into a Rare Disease. Ann Surg Oncol 19(5):1439-45, 2012. e-Pub 2012. PMID: 22187121.
268. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.
269. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23(3):652-658, 2012. e-Pub 2012. PMID: 21653683.
270. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117(19):4484-92, 2011. e-Pub 2011. PMID: 21446046.
271. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17(19):6130-9, 2011. e-Pub 2011. PMID: 21953501.
272. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz S. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011. PMID: 21855039.
273. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer 10(3):198-202, 2011. e-Pub 2011. PMID: 21855043.
274. Overman MJ, Epner DE. Lost in Translation: A Fisherman's Tale. J Clin Oncol. e-Pub 2011. PMID: 21768468.
275. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C. Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. Clin Cancer Res 17(13):4531-40, 2011. e-Pub 2011. PMID: 21551253.
276. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 2011. e-Pub 2011. PMID: 21263087.
277. Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 116(23):5374-82, 2010. e-Pub 2010. PMID: 20715162.
278. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. J Am Coll Surg 210(6):934-41, 2010. e-Pub 2010. PMID: 20510802.
279. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-55, 2010. e-Pub 2010. PMID: 20406923.
280. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 2010. e-Pub 2010. PMID: 20397775.
281. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116(6):1446-53, 2010. e-Pub 2010. PMID: 20108336.
282. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2010. PMID: 20008624.
283. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterization of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2010. PMID: 19935793.
284. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116(2):316-22, 2010. e-Pub 2010. PMID: 19904805.
285. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. e-Pub 2009. PMID: 19822514.
286. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
287. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 2009. e-Pub 2009. PMID: 19164203.
288. Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 3(3):90-6, 2009. e-Pub 2009. PMID: 19626152.
289. Fogelman DR, Overman MJ, Varadhachary G, Fortuno ME. Neoadjuvant Chemoradiation for Resectable and Borderline Pancreatic Cancer. Applied Cancer Research 28(4):127-33, 2008. e-Pub 2008.
290. Overman M, Kopetz S. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park) 22(13):1482-3, 2008. e-Pub 2008. PMID: 19227576.
291. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
292. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-54, 2008. e-Pub 2008. PMID: 18528634.
293. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. e-Pub 2008. PMID: 18798063.
294. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma. Cancer 113(8):2038-2045, 2008. e-Pub 2008. PMID: 18759326.
295. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: A report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. e-Pub 2008. PMID: 18794067.
296. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 26(12):2000-5, 2008. e-Pub 2008. PMID: 18421052.
297. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 2008. e-Pub 2008. PMID: 18083690.
298. Politano S, Overman MJ, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer 7(1):55-9, 2008. e-Pub 2008. PMID: 18279578.
299. Overman MJ, Hoff PM. EGFR-targeted Therapies in Colorectal Cancer. Dis Colon Rectum 50(8):1-13, 2007. e-Pub 2007. PMID: 17566832.
300. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 92(4):886-7, 2004. e-Pub 2004. PMID: 15499705.
301. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 17(6):1077-86, 2000. e-Pub 2000. PMID: 11078791.
302. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270(41):23895-8, 1995. e-Pub 1995. PMID: 7592576.

Invited Articles

1. Overman MJ, Morse M. Tissue-agnostic cancer therapy: DNA mismatch repair deficiency and response to immune checkpoint blockade in solid tumors. UpToDate.com, 2019. e-Pub 2019.
2. Overman MJ, Comptom CC, Raghav K. Appendiceal mucinous lesions. UpToDate.com, 2019. e-Pub 2019.
3. Cusack JC, Overman MJ. Diagnosis and staging of small bowel neoplasms. UpToDate.com, 2009. e-Pub 2009.
4. Cusack JC, Overman MJ. Treatment of small bowel neoplasms. UpToDate.com, 2009. e-Pub 2009.
5. Cusack JC, Overman MJ. Epidemiology, clinical features, and types of small bowel neoplasms. UpToDate.com, 2009. e-Pub 2009.

Editorials

1. Bhamidipati D, Anand S, Gothwal A, Raghav K, Overman MJ. On the Underreporting of Health-Related Quality of Life and Regulatory Approval. Ann Oncol. PMID: 30698646.
2. Vauthey JN, Mizuno T, Overman MJ, Soubrane O. Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?. J Hepatol 67(1):10-11, 2017. PMID: 28476639.

Abstracts

1. Overman MJ, Maurel J, Oberstein PE, Roselló-Keränen S, Le DT, Pedersen KS, Mukherjee S, D'Alise AM, Leoni G, Siani L, Scarselli E, Faivre T, Delaite P, Gogov S, Fakih M. Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer. Journal of Clinical Oncology 41(16):e14665-e14665. e-Pub 2023.
2. Lenz H, Overman MJ, Cutsem EV, M Luisa Limon M, Wong MK, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Gelsomino F, Cardin DB, Dragovich T, Shah U, McCraith SM, Wang A, Lei M, Yao J, Jin L, Lonardi S. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. Journal of Clinical oncology 41(16):3550-3550, 2023. e-Pub 2023.
3. Nasca1 H, Barretta2 F, Corti1 F, Lonardi3 H, Niger1 M, Elez4 ME, Fakih5 M, Jayachandran6 P, Shah7 AT, Salati8 M, Fenocchio9 E, Salvatore10 L, 11, Cremolini12 C, Ros13 J, 14, Ambrosini1 M, Mazzoli1 G, Intini15 R, Overman16 MJ. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. BMJ Journals 11(1). e-Pub 2023.
4. Ludford K, MD1, 2, Ho WJ, MD3, Thomas JV, MD2, Raghav KP, MBBS2, Murphy MB, MD2, Fleming ND, MD4, Lee MS, MD2, Smaglo BG, MD2, Y Nancy You Y, MD5, Tillman MM, MD5, Kamiya-Matsuoka C, MD6, Thirumurthi S, MD7, Messick C, MD5, Johnson B, DO2, Vilar E, MD, PhD8, Dasari A, MBBS2, Shin S, BS3, Hernandez A, BS3, Yuan X, MD3, Yang3 H, Foo WC, MD9, Qiao W, MS, PhD10, Maru D, MD9, Kopetz S, MD, PhD2, J Overman AM, MD2. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology, 2023. e-Pub 2023.
5. Vikas P, MD1, Messersmith H, MPH2, Compton C, MD, PhD3, Sholl L, MD4, Broaddus RR, MD5, Davis A, MPPA6, Estevez-Diz M, MD, PhD7, Garje R, MD8, Konstantinopoulos PA, MD9, Leiser A, MD10, Mills AM, MD11, Norquist B, MD12, Overman MJ, MD13, Sohal D, MD14, Turkington RC, MD, PhD15, Johnson AT, MD. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. Journal of Clinical Oncology, 2023. e-Pub 2023.
6. Overman M. COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. SITC 37th Annual Meeting, 2022. e-Pub 2022.
7. Henry J, Willis J, Parseghian CM, Singh Raghav KP, Johnson B, Dasari A, Stone D, Jeyakumar N, Coker O, Raymond VM, Lanman RB, Overman MJ, Kopetz S. NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type. ASCO Annual 2020, 2020. e-Pub 2020.
8. Lenz H, Lonardi S, Zagonel V, Cutsem EV, M Luisa Limon M, Mark Wong KY, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Spallanzani A, Cardin DB, Dragovich T, Shah U, Atasoy A, Ledeine J, Overman MJ. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. ASCO Annual 2020, 2020. e-Pub 2020.
9. Singh Raghav KP, Overman MJ, Liu S, Willett A, Royal RE, Malpica A, Scally C, Wistuba II, Futreal A, Mahvash A, Yun C, Dervin S, Mckenna EF, Schulze K, Hwu P, Yao JC, Kopetz S, Varadhachary GR, Halperin DM. A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. ASCO Annual 2020, 2020. e-Pub 2020.
10. Zhu L, Meric-Bernstam F, Holla V, Kim T, Shaw KR, Chen K, Routbort M, Kopetz S, Overman MJ. Clinical outcome for gastrointestinal cancers with polymerase epsilon mutations treated with immunotherapy. ASCO Annula 2020, 2020. e-Pub 2020.
11. Serpas V, Rogers JE, Xiao L, Mola-Rudd K, Dasari A, Kee BK, Overman MJ, Johnson B. Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC. ASCO Annual 2020, 2020. e-Pub 2020.
12. Lenz H, Lonardi S, Zagonel V, Cutsem EV, M Luisa Limon M, Wong M, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Gelsomino F, Cardin DB, Dragovich T, Shah U, Yang J, Ledeine J, Overman MJ. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. ASCO Annual 2020, 2020. e-Pub 2020.
13. Morris VK, Kee BK, Overman MJ, Fogelman DR, Dasari A, Singh Raghav KP, Shureiqi I, Johnson B, Parseghian CM, Wolff RA, Eng C, Garg N, Kopetz S. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. ASCO Annual 2020, 2020. e-Pub 2020.
14. Colina A, Singh Raghav KP, G Katz MH, Das P, Ikoma N, Koay EJ, Thomas JV, Tzeng CD, Wolff RA, Overman MJ. Pattern of recurrence after curative resection of stage I-III duodenal adenocarcinoma. ASCO Annual 2020, 2020. e-Pub 2020.
15. Singh Raghav KP, Wang XS, Xiao L, Dasari A, Morris VK, Johnson B, YC Shen JP, Parseghian CM, Kee BK, Shureiqi I, Fogelman DR, Wolff RA, Raymond VM, Odegaard JI, Lanman RB, Overman MJ, Kopetz S. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D). ASCO Annual 2020, 2020. e-Pub 2020.
16. Rocha Lima CMSP, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610). ASCO Annual 2020, 2020. e-Pub 2020.
17. Mendis SR, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary GR, Kopetz S, Overman MJ, Singh Raghav KP, Loree JM. Female representation in clinical trials leading to FDA cancer drug approvals for gastrointestinal (GI) cancers between 2008 to 2018. ASCO Annual 2020, 2020. e-Pub 2020.
18. Rocha Lima CMSP, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610). ASCO Annual 2020, 2020. e-Pub 2020.
19. Johnson B, Thomas JV, Dasari A, Singh Raghav KP, Sanchez EV, Kee BK, Eng C, Parseghian CM, Morris VK, Wolff RA, Shureiqi I, Kopetz S, Overman . A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). ASCO Annual 2020, 2020. e-Pub 2020.
20. Lenz H, Lonardi S, Zagonel V, Cutsem EV, M Luisa Limon M, Mark Wong KY, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Spallanzani A, Cardin DB, Dragovich T, Shah U, Atasoy A, Ledeine J, Overman MJ. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. ASCO Annual 2020, 2020. e-Pub 2020.
21. Sarshekeh AM, Lam M, Zorrilla IR, Holliday EB, Das P, Kee BK, Overman MJ, Parseghian CM, YC Shen JP, Tam A, Parra Cuentas ER, Zhang L, Wang X, Duose DY, Luthra R, Reddy N, Maru DM, Kopetz S, Morris VK. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC. ASCO Annual 2020, 2020. e-Pub 2020.
22. Sarshekeh AM, Roszik J, Manyam GC, Advani SM, Willis J, YC Shen JP, Morris J, Davis JS, Ajani JA, Maru DM, Overman . ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. ASCO Annual 2020, 2020. e-Pub 2020.
23. Singh Raghav KP, Willett A, Huey R, Dhillon N, Modha J, Matamoros AA, Estrella J, Sanghavi K, Antov A, Choquette L, Statz C, Kelly K, Rowe S, Liu ET, Rueter J, Kopetz S, Overman MJ, Varadhachary GR. Prospective study for comprehensive genomic profiling (GP) in cancer of unknown primary (CUP): Feasibility, molecular landscape, and clinical utility in current era. ASCO Annual 2020, 2020. e-Pub 2020.
24. Chung SW, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Singh Raghav KP, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, Davis JS. The association between female hormonal supplementation and molecular types in colorectal cancer. ASCO Annual 2019 37(suppl; abstr e15133), 2019. e-Pub 2019.
25. Hasanov M, Mohindroo C, Rogers J, Prakash L, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, G Katz MH, Kim MP, Tzeng CD, McAllister F. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. ASCO Annual 2019 37(suppl; abstr e15773), 2019. e-Pub 2019.
26. Frias RL, Lam M, Overman MJ, Morris VK, Fogelman DR, Kee BK, Dasari A, Singh Raghav KP, Shureiqi I, Jiang Z, Jensen-Loewe PA, Wolff RA, Eng C, Menter D, Kopetz S, Davis JS. Meat consumption and BRAF mutation status in colorectal cancer. ASCO Annual 2019 37(suppl; abstr e15135), 2019. e-Pub 2019.
27. Sarshekeh AM, Katkhuda R, Verma A, Advani SM, Overman MJ, Maru DM, Kopetz S. Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer. ASCO Annual 2019 37(Board #69), 2019. e-Pub 2019.
28. Lopez G, Eng C, Overman MJ, Liu W, Cohen L, Ramirez DL, Beinhorn CM, Sumler PA, Chen M, Bruera E, Prinsloo S, Li Y. A pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (CIPN). ASCO Annual 2019 37(suppl; abstr e23067), 2019. e-Pub 2019.
29. Anand S, Tannenbaum D, Horn RA, Morris VK, Johnson B, Eng C, Kopetz S, Overman MJ, Singh Raghav KP, Dasari A. A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC). ASCO Annual 2019 37(suppl; abstr e18206), 2019. e-Pub 2019.
30. Jacome AA, Kee BK, Fogelman DR, Shureiqi I, Dasari A, Singh Raghav KP, Morris VK, Johnson B, Wolff RA, Overman MJ, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Eng C. FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis. ASCO Annual 2019 37(suppl; abstr e15060), 2019. e-Pub 2019.
31. Horn RA, Tannenbaum D, Morris VK, Johnson B, Overman MJ, Parseghian CM, Kopetz S, Eng C, Rogers JE, Singh Raghav KP, Dasari A. Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization. ASCO Annual 2019 37(suppl; abstr e15055), 2019. e-Pub 2019.
32. Mohindroo C, Rogers JE, Hasanov M, Mizrahi J, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, McAllister F. A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer. ASCO Annual 2019 37(suppl; abstr e15781), 2019. e-Pub 2019.
33. Ludford K, Cohen R, Foo WC, Thomas JV, Parc Y, Svrcek M, Kopetz S, Andre T, Overman MJ. Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC). ASCO Annual 2019 37(suppl; abstr e15046), 2019. e-Pub 2019.
34. Nusrat M, Roszik J, Katkhuda R, Menter D, Singh Raghav KP, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Lizee G, Janku F, Overman MJ, Kopetz S. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). ASCO Annual 2019 37(Board #96), 2019. e-Pub 2019.
35. Lenz H, Lonardi S, Zagonel V, Cutsem EV, M Luisa Limon M, Mark Wong KY, Hendlisz A, Aglietta M, Garcia-Alfonso P, Neyns B, Cardin DB, Spallanzani A, Dragovich T, Shah U, Atasoy A, Ledeine J, Overman MJ. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. ASCO Annual 2019 37(Board #13), 2019. e-Pub 2019.
36. Parseghian CM, Willis J, Morris VK, Singh Raghav KP, Dasari A, Raymond VM, Lanman RB, Overman MJ, Kopetz S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. ASCO Annual 2019 37(Board #79), 2019. e-Pub 2019.
37. Huey R, Anand S, Rogers J, Dasari A, Varadhachary GR, Gothwal A, Loree JM, Ellis LM, Overman MJ, Singh Raghav KP. Value appraisal of FDA approved cancer drugs over the past decade. ASCO Annual 2019 37(suppl; abstr e18385), 2019. e-Pub 2019.
38. Lima Pereira AA, Parikh AR, Van Seventer EE, Jia J, Loree JM, Marie PK, Singh Raghav KP, Morris VK, Overman MJ, Raymond VM, Lanman RB, Talasaz A, Strickler JH, Corcoran RB, Kopetz S. Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). ASCO Annual 2019 37(Board #82), 2019. e-Pub 2019.
39. Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA. Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study. ASCO Annual 2019 37(Board #121), 2019. e-Pub 2019.
40. Henry J, Loree JM, Strickler JH, Singh Raghav KP, Morris VK, Raymond VM, Lanman RB, Yaeger R, Corcoran RB, Overman MJ, Kopetz S. Quantifying the evolution of tumor architecture using serial circulating tumor DNA. GI ASCO(suppl 4), 2019. e-Pub 2019.
41. Lee JJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Allegra CJ, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC). GI ASCO(suppl 4), 2019. e-Pub 2019.
42. Mizrahi J, Rogers J, Hess KR, Wolff RA, Varadhachary GR, Shroff RT, Ho L, Fogelman DR, Singh Raghav KP, Overman MJ, Pant S. FOLFIRINOX in pancreatic cancer patients age 75 years or older. GI ASCO(suppl 4), 2019. e-Pub 2019.
43. Jacome AA, Singh Raghav KP, Shaw KR, Fournier KF, Royal RE, Taggart M, Foo WC, Matamoros AA, Ahmed SU, Guerra JL, Overman MJ, Eng C. Prognostic value of genomic alterations (GA) on overall survival in appendiceal adenocarcinoma (AA). GI ASCO(suppl 4), 2019. e-Pub 2019.
44. Tannenbaum D, Singh Raghav KP, Horn RA, Overman MJ, Eng C, Kopetz S, Johnson B, Morris VK, Parseghian CM, Chang GJ, Rogers JE, Parker S, Angeles Lopez-Olivo MDL, Dasari A. Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. GI ASCO(suppl 4), 2019. e-Pub 2019.
45. Segal NH, Wainberg ZA, Overman MJ, Ascierto PA, Arkenau H, Butler MO, Eder JP, Keilholz U, Kim D, Cunningham D, Khleif SN, Doucet L, Lee J, Nemunaitis JJ, Vaishampayan UN, Weiss J, Gao C, Abdullah SE, Hollebecque A. Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. GI ASCO(suppl 4), 2019. e-Pub 2019.
46. Singh Raghav KP, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). GI ASCO(suppl 4), 2019. e-Pub 2019.
47. Jaganathan H, Roc A, Turell W, Broaddus R, Overman MJ. Improving clinician confidence and practice behavior on the therapeutic management of microsatellite-instability high (MSI-H) gastrointestinal (GI) cancers. GI ASCO(suppl 4), 2019. e-Pub 2019.
48. Overman MJ, Lonardi S, Mark Wong KY, Lenz H, Gelsomino F, Aglietta M, Morse M, Cutsem EV, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Atasoy A, Zhao H, Lei M, Kopetz S, Andre T. Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. GI ASCO(suppl 4), 2019. e-Pub 2019.
49. Serpas V, Singh Raghav KP, Varadhachary GR, Wolff RA, Overman MJ. A retrospective study of anti-EGFR antibody therapy in small bowel adenocarcinoma. ASCO 2018 36, 2018. e-Pub 2018.
50. Aldrich JD, Singh Raghav KP, Varadhachary GR, Wolff RA, Overman MJ. Retrospective analysis of taxane-based therapy in advanced small bowel adenocarcinoma (SBA). ASCO 2018 36, 2018. e-Pub 2018.
51. Overman MJ, LoRusso P, Strickler JH, Patel SP, Clarke SJ, Noonan AM, Prasanna T, Amin MA, Nemunaitis JJ, Desai J, O'Byrne KJ, George TJ, Englert J, She D, Cooper ZA, Wu Y, Khan A, Kumar R, Bendell JC. Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). ASCO 2018 36, 2018. e-Pub 2018.
52. Wang Y, Loree JM, Yu C, Tschautscher M, Briggler AM, Overman MJ, Broaddus R, Meric-Bernstam F, Jones JC, Balcom J, Kipp B, Kopetz S, Grothey A. Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer. ASCO 2018 36, 2018. e-Pub 2018.
53. Gulhati P, Yin J, Pederson L, Schmoll H, Hoff PM, Douillard J, J Randolph Hecht J, Tournigand C, Tebbut N, Chibaudel B, Gramont AD, Shi Q, Overman MJ. Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer. ASCO 2018 36, 2018. e-Pub 2018.
54. Lima Pereira AA, Lam M, Marie PK, Singh Raghav KP, Morris VK, Brown H, Windham J, Duose DY, Overman MJ, Sanchez EV, Wistuba II, Kipp P, Janku F, Sinha S, Kopetz S. Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC). ASCO 2018 36, 2018. e-Pub 2018.
55. Cruz A, Uraoka N, Parra Cuentas ER, Solis LM, A Dasari A, Overman MJ, Loree JM, Yao JC, Wistuba II, Halperin DM, Estrella J. Prognostic significance of tumor-associated macrophages in pancreatic neuroendocrine tumors. ASCO 2018 36, 2018. e-Pub 2018.
56. Nusrat M, Oh J, Jiang Z, A Dasari A, Fogelman DR, Kee BK, Menter D, Singh Raghav KP, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. ASCO 2018 36, 2018. e-Pub 2018.
57. Parseghian CM, Tam A, Yao JC, Ellis LM, Singh Raghav KP, Overman MJ. Reporting of research biopsies in clinical trials in oncology: Analysis of clinicaltrials.gov. ASCO 2018 36, 2018. e-Pub 2018.
58. Lee JJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Allegra CJ, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. ASCO 2018 36, 2018. e-Pub 2018.
59. Lam M, Lima Pereira AA, Loree JM, Advani SM, Overman MJ, Johnson A, Holla V, Khotskaya Y, Sanchez NS, Meric-Bernstam F, Kopetz S, Pant S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. ASCO 2018 36, 2018. e-Pub 2018.
60. Overman MJ, Jaimovich A, Kennedy D, Tan M, Gavino D, Mortimer S, Chudova D, Talasaz A, Odegaard J, Kopetz S. A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype. ASCO 2018 36, 2018. e-Pub 2018.
61. Sarshekeh AM, Loree JM, Manyam GC, Lima Pereira AA, Singh Raghav KP, Lam M, Davis JS, A Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The characteristics of ARID1A mutations in colorectal cancer. ASCO 2018 36, 2018. e-Pub 2018.
62. Huey R, Makawita S, Overman MJ, Ho L, Singh Raghav KP, Varadhachary GR. Clinicopathologic features and survival outcomes of sarcomatoid carcinoma presenting as cancer of unknown primary. ASCO 2018 36, 2018. e-Pub 2018.
63. Parseghian CM, Loree JM, Morris VK, Lima Pereira AA, Sanchez EV, Kee BK, Singh Raghav KP, A Dasari A, Wu J, Raymond VM, Banks K, Talasaz A, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. ASCO 2018 36, 2018. e-Pub 2018.

Book Chapters

1. Bronstein, Y, Overman, MJ, Chuang, HH, Raval, B, Silverman, PM. Small Bowel Malignant Tumors, 250-267, 2022.
2. Raghav K, Katz MHG, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancers. 5th, 2016.
3. Lieu C, Fournier K, Overman MJ, Raghav K. Cancers of the small bowel and appendix. In: MD Anderson Manual of Medical Oncology Edition 3. McGraw-Hill, 2016.
4. Bronstein Y, Overman MJ, Raval B, Silverman PM. Small bowel malignant tumors. In: Oncological Imaging: A Multidisciplinary Approach. Elsevier Saunders, 247-266, 2012.
5. Lieu C, Fournier K, Overman MJ. Cancers of the small bowel and appendix. In: MD Anderson Manual of Medical Oncology, Edition 2. McGraw-Hill, 2012.
6. Raghav K, Katz MHG, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancers. 4th, 2012.

Letters to the Editor

1. Yousef, M, Yousef, A, Hurd, MW, Balachandran Pillai, A, Chowdhury, S, Snyder, RA, Knafl, M, Lewis, RL, Roy, PM, Fanaeian, M, Albarouki, S, Castelnovo, LF, Peterson, J, Smaglo, BG, Wolff, RA, Pant, S, Willis, JA, Huey, RW, Overman, MJ, Tzeng, CW, Kim, M, Ikoma, N, Maxwell, JE, Katz, MH, Wang, H, Maitra, A, Koay, EJ, Ludmir, EB, Chen, A, Lopez, C, Ying, H, Shen, JY, Zhao, D. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology 18, 2025.
2. Maddalena, G, Zeineddine, F, Rivero-Hinojosa, S, Aushev, VN, Chowdhury, S, Zeineddine, MA, Yousef, A, Yap, TA, EINaggar, AC, Liu, MC, White, MG, Overman, MJ, Kopetz, S, Shen, JY. Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality. Annals of Oncology 35: 678-680, 2024.
3. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
4. Overman M, Wang H, Varadhachary GR. Adjuvant chemotherapy for resected periampullary adenocarcinoma. JAMA 308: 1855; author reply 1855-6, 2012.
5. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.
6. Overman M, Wang H, Varadhachary G. Comment of Neoptolemos JP et al, JAMA 308:147-56, 2012. JAMA.